BMRN Acquires ZyStor Therapeutics – Benzinga

by lowes1 on August 18, 2010


OnMilwaukee.com
BMRN Acquires ZyStor Therapeutics
Benzinga
Analysts at Piper Jaffray reiterate their "neutral" rating on BioMarin Pharmaceutical (NASDAQ: BMRN), while reducing their estimates for the company.
BioMarin snares orphan disease upstart in $115M buyoutFierceBiotech
BioMarin Buys ZyStor For $115MXconomy
Tosa biotech company acquired by California firmMilwaukee Journal Sentinel
Milwaukee Small Business Times (blog) -Contra Costa Times -Bizjournals.com
all 55 news articles »

View full post on pharmaceutical – Google News

Leave a Comment

Previous post:

Next post: